- Company
- GSK Korea appoints Maurizio Borgatta as new General Manager
- by Oct 5, 2023 05:27am
- On the 4th, GSK Korea announced it appointed Maurizio Borgatta, former General Manager of GSK Portugal as its new general manager. After joining GSK in 2015, the new GM is known to have successfully launched and sold GSK’s treatments and vaccines in the European region, including Belgium, Spain, Italy, and the UK. Also, he contributed to
- Company
- The reimbursement process for Cosentyx and Taltz
- by Eo, Yun-Ho Oct 5, 2023 05:27am
- The insurance reimbursement registration process for IL-17A inhibitors as first-line treatment for ankylosing spondylitis has been at a standstill for a long time. As a result of the investigation, the two IL-17A inhibitors approved in Korea, Cosentyx of Novartis Korea and Taltz of Lilly Korea completed discussions on expanding the HIRA leve
- Policy
- Health plans expected to be implemented after NA audit
- by Lee, Jeong-Hwan Oct 5, 2023 05:27am
- The preferential drug price policy plan that reflects the value of new drugs and the 2nd comprehensive national health insurance plan, which the pharmaceutical and bio-industry are closely eyeing, is expected to be unveiled after the National Assembly audit this year. The amendment to the Instructions for the Biohealth Innovation Committe
- Policy
- Medical expenses exceed ₩1 trillion
- by Lee, Tak-Sun Oct 4, 2023 05:35am
- The number of lung cancer patients has steadily increased, and health insurance medical expenses exceeded 1 trillion won last year. The NHIS (Chairman Jeong Ki-seok) announced this by using health insurance treatment data to promote the status of health insurance treatment for lung cancer patients from 2018 to 2022. The number of patients tre
- Company
- Price cuts for 35 generics suspended…only 0.5% of all
- by Chon, Seung-Hyun Oct 4, 2023 05:35am
- The second case of suspension of execution of price cuts among 7,000 generic drugs emerged on the 5th. The price cuts for 12 generic items from Hutecs Korea will be suspended for 9 months. The number of products for which drug price reductions have been suspended, including the 17 drugs whose price cuts have been temporarily suspended, has i
- Company
- New urothelial cancer drug Padcev attempts reimb in KOR
- by Eo, Yun-Ho Oct 4, 2023 05:35am
- Padcev, the first targeted antibody-drug conjugate (ADC) for urothelial cancer, is attempting reimbursement in Korea. According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for its Padcev (enfortumab vedotin), its antibody-drug conjugate (ADC) that is directed against Nectin-4. The drug is r
- Policy
- New pharmaceutical data protection system begins
- by Lee, Jeong-Hwan Oct 4, 2023 05:35am
- Legislation is being promoted to abolish the drug reexamination system, establish a separate legal basis for the drug data protection system, encourage research and development in the pharmaceutical industry, and strengthen the monopoly on the IMDs market. It also includes provisions to reduce the burden on pharmaceutical companies due to th
- Policy
- Legislation to prevent reverse-payment agreements
- by Lee, Jeong-Hwan Oct 4, 2023 05:35am
- Legislation is being promoted to eradicate the so-called 'generic reverse-payment agreements’ that prevent the launch of generic drugs by delaying or suspending the price cuts made on new drugs. If passed, the legislation will stipulate the reduction in the reimbursement price or suspension of reimbursement of drugs that took part in u
- Policy
- Myung-in & Hwan-in are launching Fycompa’s generics
- by Lee, Tak-Sun Sep 27, 2023 05:44am
- It is to launch early , and through this, the drug price was added 6% more than before. According to the industry on the 25th, Myungin and Hwanin will be reimbursed, respectively, on the 14th, when Fycompa material patent expires. It is launched on the market with a total of 6 dosages, and it is the first of the same ingredient in Korea. T
- Policy
- MFDS grants EUA of Moderna’s adapted COVID-19 vaccine
- by Lee, Hye-Kyung Sep 27, 2023 05:44am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyung Oh) approved the emergency use of Moderna’s monovalent vaccine ‘Spikevax Inj (andusomeran)’ that targets the COVID-19 Omicron subvariant (XBB 1.5) on September 26. The emergency use approval was granted per request by the Korea Disease Control and Prevention Agency to carry out
